End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.76 EUR | +5.29% | -4.78% | +192.98% |
May. 14 | WDH/Survey: Seven percent of adults have bought cannabis seeds | DP |
May. 09 | Medical Cannabis Group SynBiotic Buys Local Peer Weeco Pharma | MT |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+192.98% | 42.03M | - | ||
+45.37% | 4.15B | C- | ||
+135.04% | 2.24B | C | ||
+138.10% | 78.46M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- SBX Stock
- Ratings SynBiotic SE